These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 8787853)
1. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. Brem H; Ewend MG; Piantadosi S; Greenhoot J; Burger PC; Sisti M J Neurooncol; 1995 Nov; 26(2):111-23. PubMed ID: 8787853 [TBL] [Abstract][Full Text] [Related]
2. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757 [TBL] [Abstract][Full Text] [Related]
3. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Kleinberg LR; Weingart J; Burger P; Carson K; Grossman SA; Li K; Olivi A; Wharam MD; Brem H Cancer Invest; 2004; 22(1):1-9. PubMed ID: 15069758 [TBL] [Abstract][Full Text] [Related]
4. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. Olivi A; Grossman SA; Tatter S; Barker F; Judy K; Olsen J; Bruce J; Hilt D; Fisher J; Piantadosi S; J Clin Oncol; 2003 May; 21(9):1845-9. PubMed ID: 12721262 [TBL] [Abstract][Full Text] [Related]
5. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Selker RG; Shapiro WR; Burger P; Blackwood MS; Arena VC; Gilder JC; Malkin MG; Mealey JJ; Neal JH; Olson J; Robertson JT; Barnett GH; Bloomfield S; Albright R; Hochberg FH; Hiesiger E; Green S; Neurosurgery; 2002 Aug; 51(2):343-55; discussion 355-7. PubMed ID: 12182772 [TBL] [Abstract][Full Text] [Related]
6. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540 [TBL] [Abstract][Full Text] [Related]
7. Incorporating BCNU wafers into malignant glioma treatment: European case studies. Balossier A; Dörner L; Emery E; Heese O; Mehdorn HM; Menei P; Singh J Clin Drug Investig; 2010; 30(3):195-204. PubMed ID: 20155992 [TBL] [Abstract][Full Text] [Related]
8. Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas. Sai K; Zhong MG; Wang J; Chen YS; Mou YG; Ke C; Zhang XH; Yang QY; Lin FH; Guo CC; Chen ZH; Zeng J; Lv YC; Li X; Gao WC; Chen ZP J Neurol Sci; 2014 Aug; 343(1-2):60-5. PubMed ID: 24874252 [TBL] [Abstract][Full Text] [Related]
9. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. Brem H; Tamargo RJ; Olivi A; Pinn M; Weingart JD; Wharam M; Epstein JI J Neurosurg; 1994 Feb; 80(2):283-90. PubMed ID: 8283268 [TBL] [Abstract][Full Text] [Related]
10. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558 [TBL] [Abstract][Full Text] [Related]
11. A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas. Aoki T; Nishikawa R; Sugiyama K; Nonoguchi N; Kawabata N; Mishima K; Adachi J; Kurisu K; Yamasaki F; Tominaga T; Kumabe T; Ueki K; Higuchi F; Yamamoto T; Ishikawa E; Takeshima H; Yamashita S; Arita K; Hirano H; Yamada S; Matsutani M; Neurol Med Chir (Tokyo); 2014; 54(4):290-301. PubMed ID: 24739422 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861 [TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas. Rajkumar SV; Buckner JC; Schomberg PJ; Pitot HC; Ingle JN; Cascino TL Neurosurgery; 1999 Jan; 44(1):67-73. PubMed ID: 9894965 [TBL] [Abstract][Full Text] [Related]
14. Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study. Hochberg F; Prados M; Russell C; Weissman D; Evans R; Cook P; Burton G; Eisenberg PD; Valenzuela R; Verkh L J Neurooncol; 1997 Mar; 32(1):45-55. PubMed ID: 9049862 [TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801 [TBL] [Abstract][Full Text] [Related]
16. Polymeric drug delivery for the treatment of glioblastoma. Wait SD; Prabhu RS; Burri SH; Atkins TG; Asher AL Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii9-ii23. PubMed ID: 25746091 [TBL] [Abstract][Full Text] [Related]
17. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. Ali AN; Zhang P; Yung WKA; Chen Y; Movsas B; Urtasun RC; Jones CU; Choi KN; Michalski JM; Fischbach AJ; Markoe AM; Schultz CJ; Penas-Prado M; Garg MK; Hartford AC; Kim HE; Won M; Curran WJ J Neurooncol; 2018 Mar; 137(1):39-47. PubMed ID: 29404979 [TBL] [Abstract][Full Text] [Related]
18. [Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas]. Yoshida M; Yamaguchi S; Ishi Y; Endo S; Motegi H; Kobayashi H; Asaoka K; Kamoshima Y; Terasaka S; Houkin K No Shinkei Geka; 2015 Jul; 43(7):603-10. PubMed ID: 26136324 [TBL] [Abstract][Full Text] [Related]
19. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Sabel M; Giese A Curr Med Res Opin; 2008 Nov; 24(11):3239-57. PubMed ID: 18940042 [TBL] [Abstract][Full Text] [Related]
20. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. Brem H; Mahaley MS; Vick NA; Black KL; Schold SC; Burger PC; Friedman AH; Ciric IS; Eller TW; Cozzens JW J Neurosurg; 1991 Mar; 74(3):441-6. PubMed ID: 1993909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]